MedPath

FDA Sets October 2025 PDUFA Date for Xspray Pharma's Resubmitted Dasynoc Application

• The FDA has acknowledged Xspray Pharma's resubmitted New Drug Application for Dasynoc, setting a PDUFA decision date of October 7, 2025.

• Dasynoc is an amorphous dasatinib formulation developed for treating chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), with potential advantages over existing treatment options.

• The resubmission addresses a Complete Response Letter received in July 2024, with Xspray confirming it has sufficient funding to support the product through approval regardless of FDA review timeline.

The U.S. Food and Drug Administration (FDA) has set October 7, 2025, as the Prescription Drug User Fee Act (PDUFA) date for Xspray Pharma's resubmitted New Drug Application (NDA) for Dasynoc®, an amorphous dasatinib formulation for leukemia treatment.
The PDUFA date represents the FDA's deadline for communicating its decision on Xspray's application, which was resubmitted following a Complete Response Letter (CRL) received in July 2024 requesting additional information. The acknowledgment from the FDA came approximately one week later than expected, though no specific reason was provided for the delay.
"I am pleased that we now have a PDUFA date, and with that date now set we continue to prepare for a successful launch of Dasynoc® as soon as we receive market approval," said Per Andersson, CEO of Xspray Pharma. "At such point we will be ready to offer ALL and CML patients in the US Dasynoc, a dasatinib drug with important advantages compared to today's treatment options."

Clinical Application and Market Potential

Dasynoc is being developed for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The company's proprietary HyNap technology platform aims to improve upon existing protein kinase inhibitors (PKIs) for cancer treatment, potentially enhancing efficacy, safety, and patient experience.
The resubmission follows Xspray's plan communicated in January 2025. According to the company, manufacturing and quality review of new tablet batches required to address the FDA's questions have proceeded according to plan at Xspray's U.S. contract manufacturer, meeting all quality requirements.

Regulatory Timeline and Financial Outlook

The FDA can apply two different processing times for the resubmitted application—either two or six months from the resubmission date. Regardless of which timeline the FDA follows, Xspray has reiterated that it has sufficient funding to support Dasynoc through approval.
"We are well prepared to launch Dasynoc on the US market upon approval later this year," Andersson stated, indicating the company's confidence in both the regulatory outcome and its commercial readiness.

About Xspray Pharma

Xspray Pharma AB is a pharmaceutical company focused on developing improved protein kinase inhibitors (PKIs) for cancer treatment using its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving existing cancer therapies.
The Swedish company's shares are traded on Nasdaq Stockholm under the ticker XSPRAY. If approved, Dasynoc would represent a significant milestone for the company as it transitions from development to commercialization in the competitive oncology market.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Datopotamab Deruxtecan Granted FDA Breakthrough Therapy Designation for EGFR-Mutated NSCLC

The FDA granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for EGFR-mutated non-small cell lung cancer (NSCLC).
The designation is based on Phase 2 TROPION-Lung05 data, indicating a potential benefit in previously treated patients.

Datopotamab Deruxtecan BLA Submitted to FDA for EGFR-Mutated NSCLC

AstraZeneca and Daiichi Sankyo submitted a BLA to the FDA for datopotamab deruxtecan (Dato-DXd) to treat adults with metastatic or locally advanced EGFR-mutated NSCLC who have received prior treatment.
The BLA submission is based on data from the phase 2 TROPION-Lung05 study and pooled analysis from TROPION-Lung01, demonstrating enhanced efficacy in EGFR-mutant NSCLC.

AstraZeneca and Daiichi Sankyo Seek FDA Approval for Datopotamab Deruxtecan in EGFR-Mutated NSCLC

AstraZeneca and Daiichi Sankyo have submitted a Biologics License Application (BLA) to the FDA for datopotamab deruxtecan (Dato-DXd).
The BLA targets the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in patients who have previously received systemic therapies.

FDA Filing for Datopotamab Deruxtecan in EGFR-Mutated NSCLC

AstraZeneca and Daiichi Sankyo submitted a BLA to the FDA for accelerated approval of datopotamab deruxtecan in EGFR-mutated NSCLC.
The submission is based on Phase II TROPION-Lung05 trial data and supported by Phase III TROPION-Lung01 and Phase I TROPION-PanTumor01 trials.

AstraZeneca and Daiichi Sankyo Seek Accelerated Approval for Datopotamab Deruxtecan in EGFR-Mutated NSCLC

AstraZeneca and Daiichi Sankyo submitted a Biologics License Application to the FDA for datopotamab deruxtecan to treat advanced EGFR-mutated non-small cell lung cancer.
The BLA is based on Phase II TROPION-Lung05 trial results, evaluating the drug's efficacy and safety in patients who progressed after platinum-based chemotherapy and a TKI.

Aldeyra Therapeutics Resubmits NDA for Reproxalap for Dry Eye Disease Treatment

Aldeyra Therapeutics has resubmitted its New Drug Application (NDA) to the FDA for reproxalap, targeting the signs and symptoms of dry eye disease (DED).
The resubmission includes positive Phase 3 clinical trial results demonstrating reproxalap's superiority over vehicle in reducing ocular discomfort.

Xspray Pharma Plans Dasynoc NDA Resubmission After Positive FDA Meeting

Xspray Pharma plans to resubmit its New Drug Application (NDA) for Dasynoc in Q4 2024, following constructive feedback from the FDA.
The FDA recommended minor adjustments to Dasynoc's tablet strengths to mitigate medication errors, with new batches already in production.

FDA Issues Complete Response Letter for Xspray Pharma's Dasynoc in CML and ALL

The FDA issued a Complete Response Letter (CRL) for Dasynoc, Xspray Pharma's treatment for chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL).
The FDA requests additional labeling information and pre-approval inspection details, but does not question stability or clinical data.

Aldeyra Therapeutics Plans Resubmission of Reproxalap NDA for Dry Eye Disease

Aldeyra Therapeutics plans to resubmit its New Drug Application (NDA) for reproxalap to the FDA for treating dry eye disease.
A dry eye chamber clinical trial is set to begin in the first half of 2024 to support the NDA resubmission.

FDA Accepts Datopotamab Deruxtecan BLA for Nonsquamous NSCLC Treatment

The FDA has accepted the Biologics License Application (BLA) for datopotamab deruxtecan for treating advanced nonsquamous non-small cell lung cancer (NSCLC).
The BLA is based on the TROPION-Lung01 Phase III trial, which showed statistically significant improvement in progression-free survival (PFS) compared to docetaxel.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy